Author: NISREEN M.A. OKBA; Marcel A Muller; Wentao Li; Chunyan Wang; Corine H. GeurtsvanKessel; Victor M. Corman; Mart M. Lamers; Reina S. Sikkema; Erwin de Bruin; Felicity D. Chandler; Yazdan Yazdanpanah; Quentin Le Hingrat; Diane Descamps; Nadhira Houhou-Fidouh; Chantal B. E. M. Reusken; Berend-Jan Bosch; Christian Drosten; Marion P.G. Koopmans; Bart L. Haagmans
Title: SARS-CoV-2 specific antibody responses in COVID-19 patients Document date: 2020_3_20
ID: 9595vm0k_32
Snippet: Additionally, the specificity of S1 as an antigen for SARS-CoV-2 serology was further supported by the fact that 87-100 % of the cohort A-C sera included in this study were seropositive for the endemic HCoVs (HCoV-HKU1, HCoV-OC43, HCoV-NL63, and -229E) as determined by the S1 protein microarray (Figure 2B) . Nonetheless, all were seronegative for SARS-CoV and MERS-CoV. Using the same cohort, we also validated the specificity of the anti-nucleocap.....
Document: Additionally, the specificity of S1 as an antigen for SARS-CoV-2 serology was further supported by the fact that 87-100 % of the cohort A-C sera included in this study were seropositive for the endemic HCoVs (HCoV-HKU1, HCoV-OC43, HCoV-NL63, and -229E) as determined by the S1 protein microarray (Figure 2B) . Nonetheless, all were seronegative for SARS-CoV and MERS-CoV. Using the same cohort, we also validated the specificity of the anti-nucleocapsid and anti-RBD IgG ELISAs for detecting SARS-CoV-2 specific antibodies. At the set cut-off, except of SARS-CoV patient sera, none of the control sera tested positive for anti-RBD nor antinucleocapsid antibodies (Figure 2 C,D) , whereas we detected seroconversion among the three COVID-19 patients. These validated ELISAs for different antigens can be useful for epidemiological studies as well as for evaluation of vaccine-induced immune responses.
Search related documents:
Co phrase search for related documents- control sera and IgG elisa: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- control sera and immune response: 1, 2, 3, 4, 5, 6
- control sera and patient sera: 1, 2, 3, 4
- control sera and positive test: 1, 2, 3, 4, 5, 6
- control sera and SARS serology: 1
- control sera and SARS specific antibody: 1, 2, 3, 4, 5
- control sera and SARS specific antibody detect: 1
- control sera and set cut: 1
- control sera positive test and positive test: 1
- different antigen and IgG elisa: 1, 2, 3
- different antigen and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- different antigen and patient sera: 1
- different antigen and positive test: 1, 2, 3, 4, 5, 6, 7, 8
- different antigen and SARS CoV patient sera: 1
- different antigen and SARS serology: 1, 2
- different antigen and SARS specific antibody: 1, 2
- different antigen and set cut: 1
- epidemiological study and SARS serology: 1
- epidemiological study and SARS specific antibody: 1
Co phrase search for related documents, hyperlinks ordered by date